The Oncology Inflection & Space-AI Convergence — Overnight Edge Report, March 26, 2026

Market Pulse

Tonight's scan reveals a high-conviction bullish bias, with 36 bullish signals against only 7 bearish outliers. The total signal count of 43 suggests a concentrated market structure where institutional capital is rotating out of legacy software and into high-visibility growth sectors. We are seeing a distinct 'quality-growth' tilt, where earnings beats (CHWY) and regulatory wins (CORT) are being rewarded with sustained follow-through rather than immediate fades.

Key Themes

• Biotech's Multi-Indication Pivot: The surprise early FDA approval for Corcept (CORT) and the siRNA platform validation for Sarepta (SRPT) represent a structural shift in valuation for the sector. Institutions are moving from 'single-asset' risk to 'platform' appreciation.
• The Space-AI Backlog: Space is no longer a speculative frontier. With Planet Labs (PL) reporting a $900M backlog and Firefly (FLY) riding the SpaceX IPO narrative, the sector is maturing into a legitimate industrial powerhouse supported by AI-driven analytics.
• Software Structural Decay: A bearish divergence is forming in enterprise software. Regulatory threats (INTU) and competitive encroachment from AI-native players (PANW) are forcing a breach of key technical levels like the 200-day moving average.

Top Bullish Signals

• CORT (Corcept Therapeutics): The Lifyorli approval is a game-changer. Trading at an overnight score of 8, this is a 'chase' setup as the market adjusts to a new $1B+ revenue stream. Target: $55-$60.
• FLY (Firefly Aerospace): A pure-play space breakout. The combination of a 538% YoY revenue increase and the SpaceX IPO tailwind makes the $35 resistance level the primary objective.
• LMT (Lockheed Martin): A rare production-quadrupling catalyst. The framework to expand PrSM capacity provides a multi-year floor for the stock, targeting a $675 breakout.

Top Bearish Signals

• MDB (MongoDB): Institutional rejection of the Mizuho upgrade and executive departures suggest the $250 floor is about to give way. Target: $230.
• INTU (Intuit): Regulatory risk from the IRS Direct File initiative is no longer a 'tail risk'—it is being priced in. A breach of the 200DMA confirms the bearish trend.
• PANW (Palo Alto Networks): The Databricks-Anthropic entry into the SIEM market is a direct hit to PANW's platformization strategy. Technical breakdown below $152 is the entry trigger.

Best Contract Recommendations

• LMT $627.5C (4/10): Low spread (0.05%) and high conviction on the production expansion news.
• CSX $40C (4/17): A high-probability play on improving rail traffic metrics with a 225% surge in call volume.
• MDB $242.5P (4/17): Positioning for the breach of psychological support with institutional flow backing the move.
• POET $6.5C (4/10): A high RR (Risk/Reward) play ahead of the pivotal March 30 earnings call.

Divergence Watch

CVNA (Carvana) stands out as a 'fade' candidate. While the stock bounced 2.2% on macro relief (falling oil prices), institutional flow remains $41.4M bearish. This suggests the 'smart money' is using the macro bounce to exit positions ahead of further fundamental weakness.

Summary / Bias

The overnight bias is Aggressively Bullish on Biotech and Space-Defense, but Cautious/Bearish on Enterprise Software. Traders should look to buy the pullbacks in CORT and SRPT while using any relief rallies in INTU or PANW to establish short-side hedges.